Psychopharmacological Agents During Pregnancy and Nursing

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F21%3A43922633" target="_blank" >RIV/00216208:11120/21:43922633 - isvavai.cz</a>

Result on the web

<a href="https://doi.org/10.1007/978-3-319-56015-1_268-1" target="_blank" >https://doi.org/10.1007/978-3-319-56015-1_268-1</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/978-3-319-56015-1_268-1" target="_blank" >10.1007/978-3-319-56015-1_268-1</a>

Result language

angličtina

Original language name

Psychopharmacological Agents During Pregnancy and Nursing

Original language description

Decision-making about pharmacotherapy of mental disorders during pregnancy and lactation is a source of uncertainty in clinical practice. Potentially deleterious effects of drugs on the fetus and the infant are much feared; but at the same time, negative impact of untreated mental disorder have to be taken into account. Discontinuation of long-term medication increases greatly the risk of a relapse, may worsen the course of illness, and results in poor overall outcome. Drug pharmacokinetics is markedly changed throughout the pregnancy and postpartum; thus, the dosage has to be adjusted appropriately. It should be emphasized that mental disorders alone have been associated with numerous pre-, peri-, and postnatal complications and adverse effects on the fetus and the infant. Therefore, not all negative outcomes can be attributed to the medication. All psychotropic drugs cross placental barrier and pass into the maternal milk. The risk associated with drug treatment in pregnancy depends primarily on the period of exposure, gestational age. Teratogenic potential is greatest during the first trimester, neurobehavioral effects during the exposure in the last trimester, and withdrawal and intoxication with administration prior to the delivery. The chapter reviews available data on the risks and safety of antipsychotics, antidepressants, mood stabilizers, anxiolytics, hypnotics, and other psychopharmacological agents in pregnancy and nursing.

Czech name

—

Czech description

—

Type

C - Chapter in a specialist book

CEP classification

—

OECD FORD branch

30104 - Pharmacology and pharmacy

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2021

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Book/collection name

NeuroPsychopharmacotherapy

ISBN

978-3-319-56015-1

Number of pages of the result

27

Pages from-to

1-27

Number of pages of the book

754

Publisher name

Springer

Place of publication

Cham

UT code for WoS chapter

—